Specific treatments for angiotensin-converting-enzyme inhibitor (ACE-I) and angiotensin-receptor-blocker (ARB)-induced angioedema exist. Early access to these treatments is challenging because they are expensive and have short shelf lives making it illusory that all emergency department (ED) stock them. The aim of this retrospective study was to define, for each patient with a confirmed ACE-I or ARB-induced angioedema, at which step of the care, the specific treatment was administered. The second objective was to analyse the availability of these treatment in the area around Lyon, France and the factors that may influence it.
Study Type
OBSERVATIONAL
Enrollment
38
Hospices Civils de Lyon, Département d'Anesthésie-Réanimation, Hôpital Edouard Herriot, Lyon, France.
Lyon, France
Step of the care allowing the patients to benefit from a specific treatment.
Three answers are possible. Patients were treated with the specific medication (icatibant or C1-inhibitor concentrate) either in the first ED or by the medical ambulance team, or by the investigators reference center's intensive care unit.
Time frame: October 2010 to December 2014
Epidemiological characteristics
The investigators collect data such as age, sex, localization of the angioedema.
Time frame: October 2010 to December 2014
Triggering treatments
The investigators detail which ACE-inhibitor, which ARB and eventually which co-medication was taken and triggered the angioedema.
Time frame: October 2010 to December 2014
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.